Table 1 Characteristics of studies included in the network meta-analysis
Study (year) | Country | Study design | Inclusion criteria | Age | Female/male | Smoking status Systemic diseases | Intervention (T vs. C) | No. of application sites (S)/patients (P) | Application mode/site | Application period (days) |
|---|---|---|---|---|---|---|---|---|---|---|
Pradeep (2010) [28] | India | RCT | Intrabony defects, moderate (PD: 5–6 mm or CAL:4–6 mm; n = 24) to deep pockets (PD ≥ 7 mm or CAL:6–9 mm; n = 36) and vertical BL ≥ 3 mm | 30.5 ± 4.1 | 31/33 | No | SRP + SMV gel (1.2 mg/0.1 ml, 0.1 ml) (n = 30) vs. SRP + placebo gel (n = 30) | 1S/P | Subgingival | 1 |
Pradeep (2012) [29] | India | RCT | Furcation defects (buccal Class II, mandibular first and second molars), PD ≥ 5 mm and horizontal PD ≥ 3 mm | 30–50 | 34/38 | No | SRP + SMV gel (1.2 mg/0.1 ml, 0.1 ml) (n = 33) vs. SRP + placebo gel (n = 33) | 1S/P | Furcation defect | 1 |
Rath (2012) [30] | India | RCT | Intrabony defects, PD > 5 mm and vertical BL ≥ 3 mm | 25–45 | 27/33 | No | SRP + SMV gel (1.2 mg/0.1 ml, 0.1 ml) (n = 30) vs. SRP + placebo gel (n = 30) | 1S/P | Subgingival | 1 |
Pradeep (2013a) [31] | India | RCT | Intrabony defects, PD ≥ 5 mm or CAL ≥ 4 mm and vertical BL ≥3 mm | 30–50 | 32/35 | No | SRP + ATV gel (1.2 mg/0.1 ml, 10ul) (n = 30) vs. SRP + placebo gel (n = 30) | 1S/P | Subgingival | 1 |
Pradeep (2013b) [32] | India | RCT | Intrabony defects, PD ≥ 5 mm or CAL ≥ 4 mm and vertical BL ≥ 3 mm | 30–50 | 18/20 | Type 2 diabetes | SRP + SMV gel (1.2 mg/0.1 ml, 10ul) (n = 29) vs. SRP + placebo gel (n = 29) | 29S/17P vs. 29S/18P | Subgingival | 1 |
Rao (2013) [33] | India | RCT | Intrabony defects, PD ≥ 5 mm or CAL ≥ 4 mm and vertical BL ≥ 3 mm | 30–50 | Not report | Smokers (> 10 cigarettes/day for at least 5 years) | SRP + SMV gel (1.2 mg/0.1 ml, 10ul) (n = 33) vs. SRP + placebo gel (n = 34) | 33S/17P vs. 34S/18P | Subgingival | 1 |
Pradeep (2015) [34] | India | RCT | Intrabony defects, moderate (PD: 5–6 mm or CAL:4–6 mm; n = 24) to deep pockets (PD ≥ 7 mm or CAL:6–9 mm; n = 36) and vertical BL ≥ 3 mm | 25–50 | 37/33 | No | SRP + RSV gel (1.2 mg/0.1 ml, 0.1 ml) (n = 32) vs. SRP + placebo gel (n = 33) | 1S/P | Subgingival | 1 |
Kumari (2016) [35] | India | RCT | Intrabony defects, PD ≥ 5 mm or CAL ≥ 4 mm and vertical BL ≥ 3 mm | 40–50 | 37/38 | Type 2 diabetes | SRP + ATV gel (1.2 mg/0.1 ml, 10ul) (n = 30) vs. SRP + placebo gel (n = 30) | 1S/P | Subgingival | 1 |
Pradeep (2016) [36] | India | RCT | Intrabony defects, PD ≥ 5 mm, CAL ≥ 4 mm and vertical BL ≥ 3 mm | 25–45 | 45/45 | No | I: SRP + RSV gel (1.2 mg/0.1 ml, 0.1 ml) (n = 27) II: SRP + ATV gel (1.2 mg/0.1 ml, 0.1 ml) (n = 27) III: SRP + placebo gel (n = 27) | 1S/P | Subgingival | 1 and 180 (after 6 m re-deliver) |
Garg (2017) [37] | India | RCT | Mandibular Class II furcation defects, PD ≥5 mm and horizontal PD ≥ 3 mm | 30–50 | Not report | No | I: SRP + RSV gel (1.2 mg/0.1 ml,0.1 ml) (n = 30) II: I: SRP + ATV gel (1.2 mg/0.1 ml,0.1 ml) (n = 30) III: SRP + placebo gel (n = 30) | 1S/P | Subgingival | 1 and 180 (after 6 m re-deliver) |
Kumari (2017) [38] | India | RCT | Intrabony defects, PD ≥ 5 mm or CAL ≥ 4 mm and vertical BL ≥ 3 mm | 30–50 | Not report | Smokers (> 10 cigarettes/day for at least 5 years) | SRP + ATV gel (1.2 mg/0.1 ml, 10ul) (n = 33) vs. SRP + placebo gel (n = 33) | 1S/P | Subgingival | 1 |
Pradeep (2017) [39] | India | RCT | Intrabony defects, PD ≥ 5 mm or CAL ≥ 4 to 6 mm and vertical BL ≥ 3 mm | 30–50 | Not report | No | SRP + ATV gel (1.2 mg/0.1 ml, 10ul) (n = 30) vs. SRP + placebo gel (n = 30) | 1S/P | Subgingival | 1 |
Martande (2017) [40] | India | RCT | Intrabony defects, PD ≥ 5 mm or CAL ≥ 4 mm and vertical BL ≥ 3 mm | 30–50 | 46/50 | No | SRP + ATV gel (1.2 mg/0.1 ml, 10ul) (n = 30) vs. SRP + SMV gel (1.2 mg/0.1 ml, 10ul) (n = 30) vs. SRP + placebo gel (n = 28) | 1S/P | Subgingival | 1 |
Dileep P (2018) [41] | India | RCT | Intrabony defects, PD ≥ 5 mm and CAL > 3 mm | 24–41 | 29/31 | No | SRP + RSV gel (1.2 mg/0.1 ml, 0.1 ml) (n = 30) vs. SRP + placebo gel (n = 30) | 1S/P | Subgingival | 1 |